PURPOSE: To evaluate the impact of local superficial radiotherapy with respect to local control, survival, and @entity137 for @entity1 with "minimal" stage IA @entity784 ( @entity4888 ). METHODS AND MATERIALS: Between 1954 and 1996 a total of 21 @entity1 were identified as receiving curative local superficial radiation (LSR) for minimal stage IA @entity4888 . All @entity1 had pathologic documentation at diagnosis and at the time of suspected recurrences and no @entity1 received prior radiation. Ten @entity1 were treated with 100-280 Kv (A1), and 11 with 4-12 Mev electrons. Nine @entity1 had failed prior therapies ( @entity230 : 4; PUVA: 3; BCNU: 1; UVB: 1) and six received adjuvant therapy after completion of LSR (PUVA: 5; @entity230 : 1). Minimum follow-up was 1 year. RESULTS: The median follow-up was 36 months (13-246), and the median age when commencing LSR was 55 years (27-73). All @entity1 were Caucasian, and 11 were male. A total of 32 lesions were identified in 21 @entity1 ; 13 @entity1 had unilesional disease, 5 @entity1 had 2 lesions, and 3 had 3 lesions. A total of 33 fields were treated with a median treatment surface area of 107 cm2 (11-785). The median surface dose was 20 Gy (6-40), with 17 @entity1 receiving a dose > or = 20 Gy. The median fraction number was 5 for all fields, but was 10 for the fields receiving 20-40 Gy. The complete response rate was 97%, and all @entity1 were alive at last evaluation. All failures were cutaneous. One @entity1 had persistent disease (treated with 6 Gy), and three failed locally at 52 months (8 Gy), 16 months (20 Gy), and 4 months (20 Gy). None of these @entity1 received adjuvant therapy. Two @entity1 failed in distant skin sites and were salvaged. The actuarial DFS for the entire group at 5 and 10 years was 75 and 64%, respectively, with local control of 75% at both time intervals. For the 13 @entity1 with unilesional disease, the DFS was 85% at 10 years. For those treated with doses > or = 20 Gy, the DFS was 91% as was local control (no distant failures). @entity137 included mild erythema and dry desquamation acutely. Chronic @entity137 included @entity1909 [2], and @entity8721 [1]. No second cutaneous @entity1503 was noted. CONCLUSION: @entity1 with minimal Stage IA @entity4888 may be managed effectively with local superficial radiation alone without adjuvant therapy. Distant failure is unusual and @entity1 should receive a minimum surface dose of 20 Gy, which offers excellent local control. Sequalae of therapy are minimal.

Local superficial radiotherapy in the management of minimal stage IA XXXX ( @entity4888 ).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity4888 :: ('MESH:D009182', 'Disease') :: ['Mycosis Fungoides'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity8721 :: ('MESH:D013684', 'Disease') :: ['telangiectasia'] @entity784 :: ('MESH:D016399', 'Disease') :: ['cutaneous T-cell lymphoma'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['malignancies or hematologic toxicity'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']
@entity784 :: (MESH:D016399,Disease) :: ['cutaneous T-cell lymphoma']
